Compare AngloGold Ashanti Limited (AU) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Charles River Laboratories Intl. Inc — how do they compare? AngloGold Ashanti Limited trades at $97.6 (market cap $49.28B), while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: AngloGold Ashanti Limited is far larger — about 3.7× Charles River Laboratories Intl. Inc's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| AU | CRL | |
|---|---|---|
Market Cap | $49.28B | $13.46B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $282.00 |
52-Week Low | $52.15 | $145.57 |
Enterprise Value | $48.29B | $16.30B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.89, up 0.66% with strong bullish momentum from moving averages. The stock shows robust fundamentals with 32.19% net income margin and 46.5% ROE, supported by rising gold prices and production growth. Recent Q2 2026 earnings beat expectations with $727 million free cash flow, while the company maintains a $2 billion buyback program. Technical indicators show overbought conditions with RSI at 79.27, but institutional interest remains strong with multiple recent position increases.
Outlook remains positive with analyst consensus target of $120.33 (23% upside) and 64% buy ratings. Key catalysts include H2 production growth and shareholder returns, though risks include gold price volatility and operational challenges. The stock trades at reasonable valuations (P/E 13.06, EV/EBITDA 7.58) with improving balance sheet strength (debt-to-asset ratio declining to 15.59%).
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
